ESMO 2023 BioNTech Data

First-in-Human Trial Shows Promising Proof of Concept for BNT221 - a Novel Neoantigen-Focused Cell Therapy Approach Safety: BNT221 demonstrated a manageable safety profile with no DLTS. 26 Efficacy: In this aPD-1 and aCTLA-4 pretreated population, monotherapy with BNT221 resulted in tumor shrinkage for 4/9 patients Immune response: BNT221 generates a polyclonal neoantigen-specific T cell product that can be detected post-infusion Outlook: Combination of BNT221 with aPD-1 is currently being tested in the clinic. Apply translational learnings to further optimize the next-generation NEO-STIM process BIONTECH

View entire presentation